- Home
- ANL vs NTRB Comparison
ANL vs NTRB Comparison
Compare ANL & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANL | NTRB |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | Cayman Islands | United States |
| Employees | 123 | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.0M | 57.0M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANL | NTRB |
|---|---|---|
| Price | $1.85 | $4.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 1.3M | 61.4K |
| Earning Date | 02-24-2026 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,278,321.00 |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.69 |
| 52 Week Low | $0.88 | $3.90 |
| 52 Week High | $2.75 | $11.78 |
Technical Indicators
Market Signals| Indicator | ANL | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 64.46 | 45.33 |
| Support Level | $1.48 | $4.17 |
| Resistance Level | $1.71 | $4.49 |
| Average True Range (ATR) | 0.21 | 0.34 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 80.95 | 12.50 |
Price Performance
Historical ComparisonAbout ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.